Tumor suppressors revival in CLL by Carra&apos et al.
 
 





Since the 2001 FDA approval of the BCR-ABL tyrosine 
kinase inhibitor, Imatinib, as the standard of treatment 
for Chronic Myeloid Leukemia (CML), these last 16 
years have clearly showed the raise and the fall of 
strategies to target oncogenes in cancer. Beside the 
successful story of Imatinib in CML, no other drugs 
able to target oncogenes at the bench have shown such 
impressive results at the bedside. While various 
compounds have indeed clearly prompted themselves as 
effective drugs with promising clinical results, still the 
cure for cancer, meaning complete eradication, remains 
a mirage with these inhibitors.  
Conversely, murine models have proven that the re-
establishment of tumor suppressors in cancer remains 
the unique strong strategy to obtain cancer eradication: 
in a very simple, yet dramatically effective manner, 
the re-expression of p53 in various cancer models have 
indeed been associated with cancer exhaustion [1].  
For many years, the strategies to target tumor 
suppressors have been neglected from drugs cocktails. 
The idea that tumor suppressors are involved in 
tumorigenesis through genetic impairments of both 
alleles and the lack of strategies to restore these genes in 
cancer cells have wiped out all the promises in targeting 
these genes. Yet, the mechanisms of tumor suppressors 
impairment in cancer have changed: it is now clear that 
even wild-type tumor suppressors can play an essential 
role in tumorigenesis, when functionally inhibited [2]. 
Mechanisms that promote tumor suppressors de-
localization, degradation and/or inactivation inevitably 
result in tumor suppressors inhibition. The identification 
of tumors that depend on functionally inactive tumor 
suppressors is of extraordinary importance because 
these tumors can potentially benefit from therapies 
designed to restore the function of the inactive tumor 
suppressors. 
Very recently, we have demonstrated that the de-
ubiquitinase USP7, also known as HAUSP, is aberrant-
ly expressed and active in Chronic Lymphocytic 
Leukemia (CLL) [3]. Besides being one of the hundreds 
of differentially expressed genes in a cancer, USP7 has 
the privilege of controlling the expression, localization 
and function of three major tumor suppressors: PTEN [4 
-5], p53 [6] and FOXO [7].  
In this work, we demonstrated that CLL is characterized 
by an increased USP7 expression,  through  miRNA  de- 
 








regulation, and by aberrant USP7 regulation through 
Casein Kinase II. Consequently, USP7 was shown to 
promote PTEN delocalization from the nucleus with 
consequence loss of part of its tumor suppressive 
functions. Conversely, USP7 inhibitor restores PTEN 
nuclear pool with re-establishment of its tumor 
suppressive functions. In this work, we focused on the 
ability of USP7 to modulate PTEN in a p53 null 
scenario, which remains the most challenging battlefield 
for CLL therapy. However, it should be noted that 
USP7 is also well known to module p53 protein levels, 
as well [6]. USP7 promotes mdm2 de-ubiquitination, 
which in turn modulates p53 protein degradation. High 
levels of USP7 activation can indeed affect the 
mdm2/p53 network with potentially intriguing 
consequences on p53 protein levels and functional 
regulation.  Similarly, USP7 was shown to module the 
mono-ubiquitination of FOXOs, very known tumor 
suppressors able to control cellular proliferation [7]. 
USP7 favors FOXOs nuclear exclusion and 
inactivation. While we did not investigate FOXO 
cellular compartmentalization and p53 protein levels in 
CLL, it could be speculated that high levels of USP7 
may also affects FOXO localization and p53 protein 
levels in CLL.  
Our published observation that USP7-PTEN is a 
targetable network in CLL [3], and the above 
speculations that USP7 may also affect p53 and FOXOs 
in the CLL context, attribute to USP7 a potential pivotal 
role in the functional regulation of three major tumor 
suppressors in CLL. Therefore, USP7 inhibitors may 
represent strong apoptotic inducers in CLL through: i) 
the reactivation of wild-type PTEN and, potentially, p53 
and FOXO; ii) by-passing the resistance mediated by 
mutations/deletions of one of these tumor suppressors 
through the reactivation of the others, as we observed in 
the presence of p53 mutations [3]. 
In summary, our data clearly indicate that the 
characterization of molecular circuits involved in the 
control of oncosuppressor stability, localization and 
activity is critical to develop novel therapeutic strategies 
aimed at re-activating oncosuppressor functions. Thus, 
it is now advisable that USP7 inhibitors will be included 
among the drugs to be further investigated for their 
ability to positively modulate oncosuppressor regulatory 
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